Tag: Bladder cancer

In a pivotal clinical trial, Erdafitinib demonstrated a 40% objective response rate in patients with advanced urothelial carcinoma and specific genetic alterations [1.10.3]. Understanding **what is the price of Erdafitinib 4mg** is a critical step for patients considering this targeted therapy.

Non-muscle invasive bladder cancer (NMIBC) accounts for about 70-80% of new bladder cancer diagnoses. For these patients, a key question is: **how long does mitomycin stay in the bladder** during treatment? The standard dwell time is typically **1 to 2 hours**.

Thiotepa, an alkylating agent, has been a key component in cancer therapy since the 1950s and is primarily used to treat several types of cancer. It is known for its ability to interfere with the growth of cancer cells, making it a valuable tool in specific treatment regimens, especially when administered in a high-dose format or directly to a localized area.

As the first targeted therapy for bladder cancer with specific genetic mutations, Balversa (erdafitinib) represents a significant advancement in oncology. Understanding how does Balversa work involves delving into its precise mechanism of action as a potent fibroblast growth factor receptor (FGFR) inhibitor.

First isolated in 1956 from the bacterium *Streptomyces caespitosus*, the potent antineoplastic antibiotic known as mitomycin is primarily utilized today as a chemotherapy drug. The primary clinical applications that define **what is mitomycin used for** range from treating various types of cancer to preventing excessive scarring during ophthalmic surgical procedures.